AngioDynamics (ANGO) Plunges 10.70% Amid Earnings Report

AngioDynamics (ANGO) shares fell 0.58% today, marking the second consecutive day of decline, with a total drop of 10.70% over the past two days. The stock price hit its lowest level since March 2025, experiencing an intraday decline of 2.77%.

The strategy of purchasing ANGO shares upon reaching a recent low and holding for one week yielded moderate returns but underperformed the market. The annualized return of this strategy was approximately 5%, which is below the S&P 500's annualized return of 6.6% over the same period. This suggests that while the strategy provided some growth, it did not keep pace with broader market movements. Investors may want to consider this limited historical performance when deciding on their investment approach.

AngioDynamics' stock price was influenced by its Q4 fiscal 2025 earnings report, which revealed robust growth in the Med Tech segment. The company reported a total revenue of $80.2 million, reflecting over 12% year-over-year growth. This growth was primarily driven by the Med Tech division, with notable contributions from products like Auryon and mechanical thrombectomy devices.

However, the company faced several challenges that impacted its performance. A $1.6 million tariff impact affected gross margins, and there was a decrease in NanoKnife revenue. Additionally, uncertainty surrounding the regulatory pathway for the AlphaVac product's blood return feature added to the company's challenges. Despite these obstacles, analysts have increased the price target for AngioDynamics, indicating optimism about its future performance.